COMMUNIQUÉS West-GlobeNewswire

Evolus Secures $100 Million Senior Debt Facility with Oxford Finance LLC
18/03/2019
Provides Non-Dilutive Financing and Increased Flexibility Ahead of Jeuveau™ U.S. Launch NEWPORT BEACH, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer [...]
iCAD Reports Fourth Quarter and Full-Year 2018 Financial Results
18/03/2019
Company achieved key milestone in fourth quarter with FDA clearance and subsequent U.S. commercial launch of ProFound AI™ for digital breast tomosynthesis Conference call today at 4:30 p.m. ET NASHUA, N.H. , March 18, [...]
resTORbio Reports Fourth Quarter and Full Year 2018 Financial Results
18/03/2019
Positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA); Phase 3 program of RTB101 expected to initiate in 2Q19 Phase 1b/2a trial of RTB101 in combination with sirolimus in Parkinson’s disease ( [...]
Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19
18/03/2019
No Difference in Treatment Effects of Omecamtiv Mecarbil in Patients with Heart Failure Irrespective of Atrial Fibrillation SOUTH SAN FRANCISCO, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated ( [...]
IntelGenx to Report Fourth Quarter and Full-Year 2018 Financial Results on March 25, 2019 – Conference Call to Follow
18/03/2019
SAINT LAURENT, Quebec, March 18, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) today announced that it will release its fourth quarter and full year 2018 financial results after [...]
B. Braun Showcases Clinical Nutrition Portfolio at ASPEN 2019 Nutrition Science & Practice Conference
18/03/2019
BETHLEHEM, Pa., March 18, 2019 (GLOBE NEWSWIRE) -- B. Braun Medical Inc., a leader in customized parenteral nutrition, will exhibit their Clinical Nutrition portfolio at this year’s American Society for Parenteral and [...]
Amphera Recruits First Patients to Pivotal Phase II/III study of MesoPher to Treat Pleural Mesothelioma
18/03/2019
Proprietary immuno-oncology approach harnesses autologous dendritic cell therapy to treat an orphan-designated cancer `s-Hertogenbosch, The Netherlands, March 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amphera B.V [...]
DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call
18/03/2019
MINNEAPOLIS, March 18, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its 2018 financial results will be released after market close on Tuesday, March 19th. DiaMedica’s [...]
Virbac: 2018 operating profit from ordinary activities grew by 13.4%
18/03/2019
Virbac: 2018 operating profit from ordinary activities grew by 13.4% CONSOLIDATED DATA AS OF DECEMBER 31 st in € million 2018 2017 % change 2018/2017 Revenue from ordinary activities 868.9 861.9 +0.8 % Evolution at [...]
Virbac : résultat opérationnel courant 2018 en croissance de +13,4%
18/03/2019
Virbac : résultat opérationnel courant 2018 en croissance de +13,4% CHIFFRES CONSOLIDÉS AU 31 DÉCEMBRE en millions € 2018 2017 Évolution 2018/2017 Chiffre d’affaires 868,9 861,9 +0,8 % Évolution à taux de change [...]
Ossur Hf : Transactions in relation to share buyback program
18/03/2019
Announcement no. 19/2019 18 March 2019 Transactions in relation to share buyback program On 9 October 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2018. The purpose of the share [...]
Resverlogix Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone in Pulmonary Arterial Hypertension Led by Quebec Heart and Lung Institute – Laval University Researcher
18/03/2019
Resverlogix also advances its Fabry Disease indication data and planning CALGARY, Alberta, March 18, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced the advancement [...]
BioPorto A/S - Annual General Meeting
18/03/2019
March 18, 2019 Announcement no. 4 BioPorto A/S - Annual General Meeting Today, BioPorto A/S held its Annual General Meeting where the shareholders took note of the report on the Company’s activities and adopted the 2018 [...]
HPV Vaccine Mandate Ill-Advised, States Association of American Physicians and Surgeons (AAPS)
18/03/2019
TUCSON, Ariz., March 18, 2019 (GLOBE NEWSWIRE) -- Connecticut is considering legislation to end the religious exemption for mandated vaccines and to mandate human papillomavirus (HPV) vaccines for pre-teens, reports the [...]
Oasmia announces a prospectus regarding admission to trading of new shares
18/03/2019
Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) has prepared a prospectus regarding the admission to trading of the 22,948,535 shares in the Company that were issued in the directed issue which was announced [...]
BioAegis Therapeutics Completes Enrollment in its Phase 1b/2a Dose-Ranging Safety Study of Recombinant Plasma Gelsolin for Community-Acquired Pneumonia
18/03/2019
MORRISTOWN, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that it has completed patient enrollment in its Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) as adjunctive therapy [...]
Novo Nordisk A/S - Share repurchase programme
18/03/2019
Bagsværd, Denmark, 18 March 2019 - On 1 February 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 [...]
Coherus BioSciences Receives Transitional Pass-Through Status from CMS
18/03/2019
REDWOOD CITY, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that the Centers for Medicare and Medicaid Services (CMS) approved UDENYCA™ (pegfilgrastim-cbqv) [...]
Coherus BioSciences Appoints Thomas Fitzpatrick Chief Legal Officer
18/03/2019
REDWOOD CITY, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Thomas Fitzpatrick as its Chief Legal Officer. Mr. Fitzpatrick brings more than 20 years [...]

Pages